Breast cancer drug may raise diabetes risk, new study investigates

NCT ID NCT06557057

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 31 times

Summary

This study looks at how hormone therapy for breast cancer affects blood sugar control and diabetes risk. Researchers will compare blood sugar levels in postmenopausal women taking aromatase inhibitors, tamoxifen, or no treatment. The goal is to understand if these therapies increase the chance of developing diabetes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2 POSITIVE BREAST CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Mayo Clinic in Rochester

    RECRUITING

    Rochester, Minnesota, 55905, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.